Valion Bio, Inc.
VBIO
$2.40
-$0.10-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -68.40% | -55.04% | -61.28% | -49.63% | -58.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.40% | -55.04% | -61.28% | -49.63% | -58.49% |
| Cost of Revenue | 254.88% | 51.56% | -18.94% | -59.07% | -89.79% |
| Gross Profit | -429.55% | -295.95% | -160.17% | -158.94% | -85.81% |
| SG&A Expenses | 258.97% | 166.80% | 50.71% | -38.64% | -51.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 292.13% | 201.02% | 76.45% | -27.06% | -45.19% |
| Operating Income | -253.28% | -178.02% | -76.45% | 9.12% | 29.14% |
| Income Before Tax | -282.04% | -194.48% | -78.81% | 7.55% | 29.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -282.04% | -194.48% | -78.81% | 7.55% | 29.32% |
| Earnings from Discontinued Operations | -35.84% | -468.22% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.69% | -139.22% | -56.99% | -16.90% | 6.06% |
| EBIT | -253.28% | -178.02% | -76.45% | 9.12% | 29.14% |
| EBITDA | -245.87% | -178.03% | -76.46% | 9.09% | 29.14% |
| EPS Basic | 35.99% | 21.26% | -10.61% | -152.26% | -- |
| Normalized Basic EPS | 12.47% | -11.21% | -80.09% | -54.76% | -- |
| EPS Diluted | 35.99% | 21.26% | -10.61% | -152.26% | -- |
| Normalized Diluted EPS | 12.47% | -11.21% | -80.09% | -54.76% | -- |
| Average Basic Shares Outstanding | 310.21% | 400.20% | 505.75% | 745.21% | -- |
| Average Diluted Shares Outstanding | 310.21% | 400.20% | 505.75% | 745.21% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |